

# Aranzazu Fernandez-Martinez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3502138/publications.pdf>

Version: 2024-02-01

21  
papers

793  
citations

933447

10  
h-index

888059

17  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1037  
citing authors

#	ARTICLE	IF	CITATIONS
1	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	1.6	62
2	Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 509-509.	1.6	4
3	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	5.2	331
4	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
5	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	1.6	74
6	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
7	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	2.8	8
8	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019, 9, 1178.	2.8	10
9	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	1.6	6
10	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 63-70.	7.7	79
11	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 119-124.	2.4	23
12	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	1.8	17
13	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 66-66.	1.6	0
14	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	4.5	7
15	Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. <i>Immunotherapy</i> , 2016, 8, 687-692.	2.0	7
16	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. <i>Future Oncology</i> , 2016, 12, 2683-2688.	2.4	17
17	Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. <i>Cancer Treatment Communications</i> , 2016, 6, 4-7.	0.4	0
18	Prognostic value of 18F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 88-95.	0.0	9

#	ARTICLE	IF	CITATIONS
19	Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma. Annals of Oncology, 2015, 26, viii5.	1.2	0
20	Outpatient Management of Pulmonary Embolism in Cancer: Data on a Prospective Cohort of 138 Consecutive Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 365-373.	4.9	38
21	Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study. Advances in Cancer: Research & Treatment, 2013, , 1-12.	0.0	0